Niagen Bioscience reported a 20% year-over-year decline in third quarter 2026 revenue to $27.2 million, significantly missing the $33.7 million analyst estimate. The company posted a net loss of $1.2 million, or $(0.01) per share, failing to meet the projected $0.01 profit. Despite these top-line challenges, the company maintained positive Adjusted EBITDA of $0.5 million and generated $2.6 million in operating cash flow, ending the period with $69.5 million in cash and no outstanding debt.
Key Highlights
- Total Tru Niagen sales reached $23.3 million, while direct-to-consumer website sales grew 13% year-over-year.
- Total Niagen ingredient sales fell to $3.8 million, down from $6.9 million in the prior-year period due to decreased volume from key partners and competitive market dynamics.
- Gross margin compressed 160 basis points to 62.9%, primarily reflecting shifts in the business mix and operational investments.
- The company expanded its retail footprint by launching on Walmart.com and entering approximately 300 GNC and Sam’s Club locations.